NEW YORK, April 27, 2021 /PRNewswire/ -- MindMed (Nasdaq:
MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech
company, is pleased to announce the start of trading on The Nasdaq
Capital Market ("Nasdaq"). Trading will begin on Tuesday, April 27, 2021, under the symbol "MNMD"
on the Nasdaq.
As a reminder, MindMed will retain its listing on the Neo
Exchange Inc. under the symbol "MMED". Once trading begins, the
Company's subordinate voting shares will convert from the OTCQB
under the symbol "MMEDF" to the new symbol "MNMD".
Furthermore, there will be a live bell ringing ceremony for
MindMed on Thursday during the opening bell. Please use the
following link to stream it live:
https://livestream.com/accounts/27896496/events/9614244
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that discovers, develops and deploys psychedelic inspired medicines
and therapies to address addiction and mental illness. The company
is assembling a compelling drug development pipeline of innovative
treatments based on psychedelic substances including Psilocybin,
LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed
executive team brings extensive biopharmaceutical experience to
MindMed's approach to developing the next generation of
psychedelic-inspired medicines and therapies.
MindMed trades on the Canadian exchange NEO under the symbol
MMED and in Germany under the
symbol MMQ. MindMed will commence trading on the Nasdaq under the
symbol MNMD effective April 27, 2021;
until then the Company will continue to trade in the United States under the symbol MMEDF on
the OTCQB.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include statements related to the anticipated benefits to the
Company and its shareholders related to the listing on the Nasdaq
and future plans and objectives of the Company. Although the
Company believes that the expectations reflected in such
forward-looking information are reasonable, such information
involves risks and uncertainties, and undue reliance should not be
placed on such information, as unknown or unpredictable factors
could have material adverse effects on future results, performance
or achievements of the Company. There are numerous risks and
uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information, including history of negative cash
flows; limited operating history; incurrence of future losses;
availability of additional capital; lack of product revenue;
compliance with laws and regulations; difficulty associated with
research and development; risks associated with clinical trials or
studies; heightened regulatory scrutiny; early stage product
development; clinical trial risks; regulatory approval processes;
novelty of the psychedelic inspired medicines industry; as well as
those risk factors discussed or referred to herein and the risks
described under the heading "Risk Factors" in the annual
information form for the year ended December
31, 2020 and in other filings filed with the securities
regulatory authorities in all provinces and territories of
Canada and available under the
Company's profile on SEDAR at www.sedar.com and as described in the
information furnished to or filed with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Should one or
more of these risks or uncertainties materialize, or should
assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact:
mindmed@150bond.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mindmed-begins-trading-on-nasdaq-301277544.html
SOURCE Mind Medicine (MindMed) Inc.